{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"972","upperLimit":"1450","value":"1211"},{"groupId":"OG001","lowerLimit":"521","upperLimit":"4070","value":"2143"},{"groupId":"OG002","lowerLimit":"1520","upperLimit":"3168","value":"2193"},{"groupId":"OG003","lowerLimit":"559","upperLimit":"3301","value":"1410"},{"groupId":"OG004","lowerLimit":"952","upperLimit":"4253","value":"2359"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"description":"On day 21 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 1, 2, 4, 8 (±1), 10 (±0.5) optional, and 24 (±4) hours after the dose. Area under the plasma concentration time curve (AUC) was estimated using a non-compartmental method.","dispersionType":"Full Range","groups":[{"description":"Less-heavily pre-treated patients received oral palbociclib daily at 50 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Stratum I, Dose Level 1 (50 mg/m2)"},{"description":"Less-heavily pre-treated patients received oral palbociclib daily at 75 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Stratum I, Dose Level 2 (75 mg/m2)"},{"description":"Less-heavily pre-treated patients received oral palbociclib daily at 95 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Stratum I, Dose Level 3 (95 mg/m2)"},{"description":"Heavily pre-treated patients received oral palbociclib daily at 50 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"Stratum II, Dose Level 1 (50 mg/m2)"},{"description":"Heavily pre-treated patients received oral palbociclib daily at 75 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"Stratum II, Dose Level 2 (75mg/m2)"}],"paramType":"MEDIAN","populationDescription":"Patients with blood samples collected for pharmacokinetic studies on days 21-22 of course 1 were included.","reportingStatus":"POSTED","timeFrame":"Up to day 22","title":"Steady State Area Under the Plasma Concentration Time Curve (AUC)","type":"PRIMARY","unitOfMeasure":"h*ng/mL"}